Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anti-CLL-1 CAR-T (The Affiliated Hospital of Xuzhou Medical University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Anti-CLL-1 CAR-T (The Affiliated Hospital of Xuzhou Medical University): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP,
9 min read
SHCW-8602 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
SHCW-8602: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
WT1-Sensitized Allogeneic T-Lymphocytes(Atara Biotherapeutics/Memorial Sloan Kettering Cancer Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
WT1-Sensitized Allogeneic T-Lymphocytes(Atara Biotherapeutics/Memorial Sloan Kettering Cancer Center): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review cov
9 min read
Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical ) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Anti-MUC1 CAR-T (Shenzhen Geno-Immune Medical ): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, marke
9 min read
Prizloncabtagene autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Prizloncabtagene autoleucel: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key
9 min read
ABBV-273 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ABBV-273: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
![[212Pb]Pb-ADVC001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_B_86_48077a7b89.jpg)
9 min read
[212Pb]Pb-ADVC001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
[212Pb]Pb-ADVC001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Recombinant human thrombopoietin mimetics(Shandong Quangang Pharmaceutical Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Recombinant human thrombopoietin mimetics(Shandong Quangang Pharmaceutical Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical deve
9 min read
IMM-040811 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
IMM-040811: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Abipapogene Suvaplasmid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Abipapogene Suvaplasmid: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risk
9 min read
nL-PACS1-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
nL-PACS1-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SPK-10001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
SPK-10001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.